MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cpcardiol.2024.102451

Медицинская библиотека · Current problems in cardiology · 2024

Safety and efficacy of antithrombotics in outpatients with symptomatic COVID-19: A systematic review and meta-analysis.

Ansari Saad Ali, Merza Nooraldin, Salman Madiha, Raja Adarsh, Sayeed Bushra Zafar, Rahman Hafsah Alim Ur, Bhimani Sunaina, Shaikh Afrah Saeed, Naqi Unaiza, Farooqui Areeba, Afridi Simra, Feroze Ahsan, Hameed Ishaque

МетаанализСистематический обзорСтатьяПеревод в очереди

Аннотация

BACKGROUND

Coronavirus disease (COVID-19) is a global health emergency, with well over six hundred million infections and over six million deaths to date. Besides other ramifications, it is also associated with inflammation and an augmented risk of thromboembolic complications. Despite this, the risks and benefits of antithrombotic drugs in patients with mild to moderate COVID-19 have not been well-established and remain controversial.

OBJECTIVES

To evaluate the safety and efficacy of antithrombotic drugs on mild to moderate symptomatic COVID-19 patients by performing an updated systematic review and meta-analysis.

METHODS

We queried electronic databases (PubMed, Cochrane Central, Scopus, and Embase) from their inception up to September 2022 for randomized controlled trials comparing antithrombotic drugs against placebo. The outcomes of interest were the need for hospital care, mortality, and thromboembolic events in the enrolled participants. Dichotomous outcomes were presented as risk ratio (RR) with 95 % confidence intervals (CIs) and were consolidated using random-effects model.

MAIN

RESULTS

Five eligible studies (Rivaroxaban/Apixaban, two; enoxaparin, two; Sulodexide, one), consisting of 2,005 participants with mild to moderate COVID-19, were included. Pooled results show that antithrombotics, when compared to placebo, do not significantly reduce all-cause mortality (RR 0.51, 95 % CI 0.15-1.68; P = 0.27; I2 = 0), thromboembolic events (RR 0.78, 95 % CI 0.17-3.51; P = 0.74; I2 = 0), need for hospitalization (RR 0.73, 95 % CI 0.51-1.03; P = 0.08; I2 = 0), nor significantly increase clinically relevant non-major bleeding events (RR 2.36, 95 % CI 0.56-9.89; P = 0.24; I2 = 0). However, when Sulodexide was compared independently to other antithrombotics, it significantly reduced the need for hospitalization (RR 0.60, 95 % CI 0.37-0.95; P = 0.03).

CONCLUSIONS

Our pooled analysis was not able to establish statistically significant benefits or risks of using antithrombotic drugs in mild to moderate COVID-19 patients. To further improve our understanding of the efficacy, safety and risk profile of such a therapy, large sample randomized clinical trials are required on a wide scale.

Для цитирования: Ansari Saad Ali, Merza Nooraldin, Salman Madiha, Raja Adarsh, Sayeed Bushra Zafar, Rahman Hafsah Alim Ur, Bhimani Sunaina, Shaikh Afrah Saeed, Naqi Unaiza, Farooqui Areeba, Afridi Simra, Feroze Ahsan, Hameed Ishaque. Safety and efficacy of antithrombotics in outpatients with symptomatic COVID-19: A systematic review and meta-analysis.. Current problems in cardiology. 2024. DOI: 10.1016/j.cpcardiol.2024.102451.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.